First procedures to be performed in the coming weeks at Alabama’s largest non-governmental healthcare system
Purchase funded by the Thomas Foundation following FDA marketing authorization of ProSense® in low-risk breast cancer and inclusion of cryoablation in proposed medical society guidelines
IceCure Medical Ltd. (NASDAQ: ICCM) (“IceCure”, “IceCure Medical” or the “Company”), a developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced Thomas Hospital of Fairhope, Alabama, part of the Infirmary Health network of hospitals, purchased and installed the ProSense® system, becoming the first facility in Alabama to offer breast cancer cryoablation. Dr. Katelin Holmes, a board-certified breast surgeon, Medical Director of Breast Surgical Services at Thomas Hospital, and Co-Director of the National Accreditation Program for Breast Centers (“NAPBC”) Breast Program, will be selecting patients for the procedures, some of which are scheduled to commence their treatment this month.
“Thomas Hospital and Infirmary Health are leading the advancement of breast care in Alabama, where they serve a large population of women from around the Gulf Coast region. We are very pleased that with ProSense®, they will provide the very first breast cancer cryoablation procedures in Alabama over the coming weeks,” stated IceCure’s Vice President of Sales, North America, Shad Good. “We believe the installation comes on the heels of increased interest in ProSense® following the October 2025 Food and Drug Administration (“FDA”) clearance for the local treatment of low-risk breast cancer, and we have observed a growing awareness that may lead to more installations over the coming months.”
The hospital’s purchase was made possible by the Thomas Hospital Foundation, a nonprofit organization dedicated to supporting Thomas Hospital to access state-of-the-art medical technology to offer innovative and compassionate care for their patients.
Mr. Good continued, “We are highly encouraged that the system was purchased by the Thomas Hospital Foundation as part of its mission to be a leader in delivering the most innovative treatments to patients in their community. Based on the hospital network’s patient volume and population, it is our hope that a large number of eligible women will benefit from ProSense® as a minimally invasive treatment option.”
Nathan Payne, J.D., M.Ed., Director of the Thomas Hospital Foundation, added, “This technology represents a meaningful step forward for breast care on the Eastern Shore, bringing advanced, less invasive treatment options to patients at Thomas Hospital. The Foundation’s role is to thoughtfully steward donor generosity, so we are prepared to invest in innovative, cutting-edge care when opportunities like this arise. It’s exciting to see how local philanthropy continues to move healthcare forward at Thomas.”
